Gene-editing therapies face a tough road ahead, notes BI senior biopharmaceuticals analyst Ann-Hunter van Kirk. Despite CRISPR and
@VertexPharma securing the first
@US_FDA approval, the market’s launch has been underwhelming, pushing revenue projections down to $5B by 2030 from earlier $13B forecasts. High costs, uncertain reimbursement models, and elevated interest rates continue to pressure the largely precommercial sector. By 2035, CRISPR Therapeutics could still lead with 28% of market share, followed by Verve,
@Intellia Therapeutics, Inc. and Beam. The industry’s future hinges on adapting payment structures for multimillion-dollar, one-time treatments to unlock broader adoption and sustain long-term growth.
#pharma #Merger #gene-eding
#fda